Holen Sie sich die Stockscreener-App
39.36
0.98%
-0.29
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics adds Christopher Hite to board of directors - Investing.com India
Vera Therapeutics appoints Christopher Hite to board of directors - marketscreener.com
Vera Therapeutics Appoints Christopher Hite To Board Of Directors - TradingView
Royalty Pharma vice chair joins Vera board before potential IgA drug launch - Stock Titan
Q1 EPS Estimates for Vera Therapeutics Cut by HC Wainwright - MarketBeat
Vera Therapeutics Files BLA for Atacicept in IgAN, Target Action Date July 7, 2026 - Intellectia AI
Vera Therapeutics, Inc. (VERA) Stock Analysis: 94.88% Potential Upside Signals Compelling Opportunity - DirectorsTalk Interviews
HC Wainwright Issues Positive Forecast for Vera Therapeutics (NASDAQ:VERA) Stock Price - MarketBeat
VERA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vera Therapeutics Raises $261M in Public Offering at $42.50 per Share - Intellectia AI
Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA) - Sahm
Trading Systems Reacting to (VERA) Volatility - Stock Traders Daily
Key facts: Vera Therapeutics submits atacicept BLA; posts $299.6M loss - TradingView
Wedbush Raises Price Target on Vera Therapeutics to $35 From $33, Keeps Neutral Rating - marketscreener.com
Does FDA Priority Review And Phase 3 Win For Atacicept Redefine The Bull Case For Vera (VERA)? - Yahoo Finance
VERA Should I Buy - Intellectia AI
Vera Therapeutics, Inc. SEC 10-K Report - TradingView
Atacicept progress puts Vera Therapeutics (NASDAQ: VERA) at key FDA milestone - Stock Titan
Vera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
VERA: FDA priority review and strong cash reserves set the stage for atacicept's 2026 launch - TradingView
BRIEF-Vera Therapeutics FY EPS USD -4.66 Vs. IBES Estimate USD -4.55 - TradingView
Vera Therapeutics (VERA) widens 2025 loss as atacicept wins FDA priority review - Stock Titan
Biotech bets on kidney drug: Vera raises $800M after $299.6M loss - Stock Titan
Vera Therapeutics (NASDAQ:VERA) SVP Sells $130,851.66 in Stock - MarketBeat
Vera Therapeutics (NASDAQ:VERA) Insider Laurence Matthew Skelton Sells 1,582 Shares - MarketBeat
Insider Selling: Vera Therapeutics (NASDAQ:VERA) Insider Sells 2,187 Shares of Stock - MarketBeat
Insider Selling: Vera Therapeutics (NASDAQ:VERA) COO Sells 2,579 Shares of Stock - MarketBeat
Vera Therapeutics (VERA) CEO executes 16,925-share tax sell-to-cover trade - Stock Titan
Vera Therapeutics (VERA) CCO sells 1,582 shares in RSU tax sale - Stock Titan
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results - Bitget
Sean Grant Sells 4,949 Shares of Vera Therapeutics (NASDAQ:VERA) Stock - MarketBeat
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics, Inc. (VERA) Stock Analysis: Exploring a 78.68% Potential Upside in Biotechnology - DirectorsTalk Interviews
Broker files Rule 144 to sell 1,800 VERA shares (NASDAQ: VERA) - Stock Titan
Morgan Stanley to sell 2,600 VERA shares (NASDAQ: VERA) under Rule 144 - Stock Titan
VERA (NASDAQ: VERA) notice of 5,700-share sale via Form 144 - Stock Titan
Morgan Stanley Smith Barney reports sale of 2,500 VERA shares (VERA) - Stock Titan
[144] Vera Therapeutics, Inc. SEC Filing - Stock Titan
VERA (NASDAQ: VERA) files Rule 144 sale notice for 16,600 shares - Stock Titan
Options Flow: How cyclical is Vera Therapeutics Incs revenue streamBear Alert & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing Vera Therapeutics (VERA) Valuation After Atacicept Phase 3 Success And Analyst Downgrade - Sahm
Vera Therapeutics: Hold Rating Based On Potential For Atacicept In IgAN (Rating Downgrade) - Seeking Alpha
Published on: 2026-02-20 18:05:40 - mfd.ru
Analysts bullish on Vera Therapeutics (VERA) amid new commercial chief appointment - MSN
Analysts Bullish on Vera Therapeutics (VERA) Amid New Commercial Chief Appointment - Insider Monkey
Death Cross: What is the earnings history of Vera Therapeutics Inc2025 Trading Recap & Fast Entry High Yield Tips - baoquankhu1.vn
Vera Therapeutics (VERA) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Panic Selling: Should I buy Vera Therapeutics Inc stock nowWeekly Trade Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - MSN
T. Rowe Price holds 7.7% of Vera Therapeutics (VERA) common stock - Stock Titan
How Vera Therapeutics Inc. (VERA) Affects Rotational Strategy Timing - Stock Traders Daily
Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA) - Yahoo Finance
Atacicept's Potential Approval Drives Favorable Views on Vera Therapeutics (VERA) - Finviz
Vera Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4) - Intellectia AI
B of A Securities Begins Coverage of Vera Therapeutics with a Buy Rating and Sets Price Target at $48 - Intellectia AI
17 Biotechnology Stocks with More Than 50% Upside - Insider Monkey
Breakout Watch: What is Vera Therapeutics Incs debt to equity ratioPortfolio Update Summary & Community Trade Idea Sharing - baoquankhu1.vn
What is the next catalyst for Vera Therapeutics Inc.Gap Up & Long-Term Growth Plans - mfd.ru
Vera Therapeutics, Inc. $VERA Shares Purchased by Candriam S.C.A. - MarketBeat
Vera Therapeutics, Inc. (VERA) Stock Analysis: A 71% Upside Potential In The Biotech Arena - DirectorsTalk Interviews
Vera Therapeutics, Inc. (VERA): A Bull Case Theory - Insider Monkey
Assessing Vera Therapeutics (VERA) Valuation As Atacicept Nears FDA Decision And Commercial Leadership Shifts - Sahm
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):